The first compact and easy-to-use microreactor device for Body-On-Chip experiments.

Informations projet

B-On-Chip

N° de convention de subvention: 762315

DOI

10.3030/762315

Projet clôturé

Date de signature de la CE 23 Janvier 2017

Date de début 1 Janvier 2017

Date de fin 31 Mai 2017

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

BEONCHIP SL
Spain

Periodic Reporting for period 1 - B-On-Chip (The first compact and easy-to-use microreactor device for Body-On-Chip experiments.)

Période du rapport: 2017-01-01 au 2017-05-31

Résumé du contexte et des objectifs généraux du projet

BEOnChip S.L. is a leading company focused on the field of Micro-biotechnology. We count on a patent portfolio of microfluidic chips to be used as organ-on-chips that can be defined as micro-sized artificial organs with the unique ability to host different cells to mimic human-type responses to new drugs. Now, in the B-On-Chip project we seek bringing to the market the first compact, fully automated and easy-to-use device to link multiple organs-on-chip, enabling the so-called body-on-chip experiments. The use of B-On-Chip by the Pharma industry has the potential to reduce the use of laboratory animals, to accelerate drug development and to study how reactions in one organ affect another. Therefore, B-On-Chip will offer the most accurate in vitro data on new drug efficiency, security, and toxicity in a fast, automatic and reliable way.

OBJECTIVES FOR THE ACTION

F.0.1-To search for and identify potential suppliers of Microreactor technology components in EU.
F.0.2- To build up a work plan for final technology development: key milestones, tasks and risk analysis.
F.0.3-To search for and identify potential distributors in EU and define our commercialization strategy
F.0.4-To define our IP strategy and perform a patentability analysis.
F.0.5-To perform a market analysis to define the best channels for entering different geographic markets.
F.0.6- Preparation of a business plan for the next 5 years.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The work performed and the main achievements have been the following:
 We have performed an in-depth research of all companies dedicated to supply, develop and manufacture components for microfluidic technology
 We have defined a precise 2-years work plan for technology development together with a risk management plan.
 We have performed a careful analysis of distributors.
 We have performed a patentability and freedom to operate analysis.
 We have performed an exhaustive market research study.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The B-on-Chip project will not only benefit the pharmaceutical industry allowing them to reduce the long time and huge costs required for new drugs development, but it will also allow: 1) developing new, cheaper and more efficient drugs, 2) developing new biomarkers for diagnosis. All this will lead to a better quality of life for patients and life expectancy, the reduction of expenses by healthcare system.

imagen.png